Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.52 |
| ▸ | NPY1R | P25929 | 7/20 | 0.52 |
| ▸ | NPY2R | P49146 | 5/20 | 0.52 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.52 |
| ▸ | MME | P08473 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 1/20 | 0.48 |
| ▸ | GNPAT | O15228 | 1/20 | 0.47 |
| ▸ | FNTA | P49354 | 3/20 | 0.45 |
| ▸ | FNTB | P49356 | 3/20 | 0.45 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.45 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29628189 | 0.98 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29628224 | 0.97 | NPY4R (0.51) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL31154635 | 0.96 | NPY4R (0.49) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29628380 | 0.95 | NPY4R (0.54) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29850918 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30866590 | 0.94 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL30401538 | 0.94 | NPY4R (0.55) | NPY4RNPY1RNPY2RNPY5RKISS1R | |
| SCHEMBL29800344 | 0.93 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL29652150 | 0.93 | NPY4R (0.56) | NPY4RNPY1RNPY2RNPY5RMME | |
| SCHEMBL23142771 | 0.92 | NPY4R (0.58) | NPY4RNPY1RNPY2RNPY5RKISS1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2025-04-24 | — | — | US | disclosed |
| EP-4541378-A2 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | Endocyte, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-12178892-B2 | Compounds for positron emission tomography | PURDUE RESEARCH FOUNDATION (US) | 2024-12-31 | — | — | US | disclosed |
| CN-117589983-A | Kit for detecting foot-and-mouth disease virus antibody and/or vesicular stomatitis virus | 上海鸣捷生物科技有限公司 | 2024-02-23 | — | — | CN | disclosed |
| US-20230331781-A1 | PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF | HADASIT MEDICAL RESEARCH SERVICES AND DEVELOPMENT LTD. (IL) | 2023-10-19 | — | — | US | disclosed |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | PURDUE RESEARCH FOUNDATION | 2022-04-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250127939-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | VHL, PC, NPC1 | NPY4R 4297/4885NPY1R 4092/4885NPY2R 4312/4885 |
| US-12178892-B2 | Compounds for positron emission tomography | FOLH1, FOLR2, FOLR1 | NPY4R 2363/4885NPY1R 1152/4885NPY2R 1595/4885 |
| US-20220125958-A1 | COMPOUNDS FOR POSITRON EMISSION TOMOGRAPHY | FOLH1, FOLR2, FOLR1 | NPY4R 2363/4885NPY1R 1152/4885NPY2R 1595/4885 |
| US-20230331781-A1 | PAR4 DERIVED PEPTIDES, ANALOGS AND USES THEREOF | ERBB4, F2RL3, ERBB3 | NPY4R 98/4885NPY1R 462/4885NPY2R 853/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.